Key clinical point: Pediatric cancer patients exposed to anthracycline and nonanthracycline chemotherapy had a higher risk of developing several types of cardiovascular disease 10 years after treatment.
Major finding: Compared with cancer-free controls, 203 children who survived cancer experienced at least one cardiac event (2.8% vs. 0.9%; P less than .001).
Study details: A population-based matched cohort study of cardiovascular disease risk among 7,289 pediatric cancer survivors from the Pediatric Oncology Group of Ontario Networked Information System treated between 1987 and 2010 and 36,205 matched cancer-free individuals.
Disclosures: This study was funded in part from a grant by the Canadian Institutes for Health Research. Several authors reported support from noncommercial sources. The other authors reported having no relevant conflicts of interest.
Khanna A et al. Circulation. 2019 Aug 26. doi: 10.1161/CIRCULATIONAHA.119.041403.